Inspiratory hyperoxia: a new way to prevent metastasis through metabolism reprogramming in non-small cell lung cancer

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases. In the past decades, significative improvements in the clinical management of NSCLC patients have been made, first with the introduction of targeted therapies, such as inhibitors of the tyrosine kinase activity of epidermal growth factor receptor (EGFR) in EGFR-mutated NSCLC patients, and even more with the introduction of immune checkpoint inhibitors in NSCLC patients with high PD-L1 expression [2, 3]. However, despite impressive results, first responder patients always develop resistance, which correlates with disease progression. In addition, a significant proportion of NSCLC patients remains ineligible for these therapies or, even when eligible, does not respond. Therefore, the identification of new therapeutic strategies is of critical importance in NSCLC. When hyperoxia meets metabolism in non-small cell lung cancer https://bit.ly/3Bj2Vvr